Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Oncol.

Sec. Cancer Molecular Targets and Therapeutics

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1569897

This article is part of the Research TopicNovel Molecular Targets in Cancer TherapyView all 45 articles

TROP2: as a promising target in lung cancer

Provisionally accepted
Xing  xing LiXing xing Li1,2*Jia  li ChenJia li Chen1,2
  • 1The First People's Hospital of Linping, Hangzhou, China
  • 2Department of Medical Oncology, Hangzhou, China

The final, formatted version of the article will be published soon.

Lung cancer (LC) is a significant global health concern, underscoring the need for ongoing research into novel therapeutic modalities. Trophoblast cell surface antigen-2 (TROP2) is overexpressed in tumor tissues and minimally expressed in normal tissues, making it a promising target for cancer treatment. A TROP2-targeted antibody-drug conjugate (ADC) has been approved by the Food and Drug Administration (FDA).This review aims to provide a comprehensive overview of the characteristics of TROP2 and its role in cancer development. It is imperative to acknowledge the significant advancements made in the realm of LC therapy through the development of ADCs that specifically target the TROP-2 antigen. The potential of the TROP-2 ADC in the treatment of LC is a subject of considerable promise, suggesting a promising future in the therapeutic management of this condition.

Keywords: Tacstd2, Trop2, Antibody-drug conjugate, lung cancer, Lung Adenocarcinoma

Received: 05 Mar 2025; Accepted: 04 Aug 2025.

Copyright: © 2025 Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xing xing Li, The First People's Hospital of Linping, Hangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.